Why Microbiome Science Belongs in Intimate Health
Intimate woman’s health conditions remain one of the most structurally under-invested areas in healthcare. Bacterial vaginosis (BV) and vulvovaginal candidiasis (thrush) affect over 1 billion women globally every year. In the UK alone, 1 in 3 women experience BV, while 1 in 20 suffer at least once in their lifetime thrush. Beyond physical discomfort, these conditions carry real emotional and social weight, including stigma and, in pregnancy, increased risk of complications such as preterm birth.
Despite affecting millions, treatment options have not meaningfully advanced in decades.
The problem with today's standard of care
Current therapies largely operate on the same premise: kill off bacteria, or acidify the environment. In practice, this approach can do as much harm as good.
- Microbiome disruption: Antibiotics and antifungals kill beneficial lactobacilli alongside harmful pathogens, leaving the intimate environment stripped of its natural defences.
- High recurrence: Up to 50% of women experience infection recurrence within just three months, trapping them in a cycle of repeated treatment.
- Irritation from added acid: Acid-containing gels frequently cause localised buning and soreness, leading many women to discontinue use.
- Antimicrobial resistance (AMR): Over-reliance on antibiotics and antifungals contributes directly to a growing global resistance problem.
The BiotaLife difference: science-led, microbiome-first
BiotaLife Healthcare is a MedTech company on a mission to deliver microbiome-first intimate health. Developed in collaboration with researchers at King's College London (KCL) and UCL, BiotaLife products are designed to work with the body, not against it.
Rather than suppressing bacteria indiscriminately, our patented technology feeds native Lactobacillus species with glycogen, selectively supporting beneficial bacteria and helping restore a healthy pH, rather than crowding out pathogens through force.
How this compares to current options
|
Feature & Benefit |
BiotaLife Healthcare |
Traditional Antibiotics Antifungals |
OTC Acid-Containing Gels |
|---|---|---|---|
|
Antibiotic & Antifungal-Free |
Yes. Zero risk of driving drug resistance |
No. Indiscriminately wipes out native flora |
Yes. But lacks targeted prebiotic action |
|
Acid-Free (No Irritation) |
Yes. Gentle, neutral pH hydrogel |
N/A. Systemic or localized anti-infectives |
No. High acidity causes burning and soreness |
|
Dual-Action Capability |
Yes. Treats BV and thrush drivers in one go |
No. Targeted at only one pathogen type |
No. Fails to restore lactobacilli balance |
|
Recurrence Reduction |
High. Rebuilds long-term native microbiome |
Low. 30–50% recurrence within 3 months |
Low. Offers temporary relief only |
|
Academic Credibility |
Yes. Co-developed with KCL & UCL |
Varies. Standard pharmaceutical formulas |
No.Generic commercial formulations |
Our product portfolio
DuoBalance™ (candidate medical device)
Currently under regulatory development for launch as an OTC medical device.
An estimated 62% of women misdiagnose BV as thrush, taking the wrong treatment and worsening their symptoms. DuoBalance is designed to address the dysbiosis underlying both conditions together.
Early laboratory testing indicates a single application increases protective lactobacilli while reducing Candida species and Streptococcus agalactiae (GBS) carriage. Full data to follow on publication.
Free from synthetic drugs and harsh acids, DuoBalance is designed to avoid the irritation and microbiome disruption associated with legacy products.
BloomCalma™ (launching November 2026)
Formulated specifically for the pregnancy and postpartum life stage. Pregnancy and childbirth bring significant hormonal shifts and physical changes to intimate tissue, and BloomCalma is designed to offer soothing hydration without irritants, supporting daily comfort during recovery.
Our commitment
Intimate health shouldn't be a source of shame or ongoing frustration. By bringing together academic research and thoughtful product design, BiotaLife is working to replace outdated interventions with evidence-based microbiome support, from BloomCalma's everyday comfort to DuoBalance's dual-action approach for recurrent infection.
FAQ
What is DuoBalance?
DuoBalance is BiotaLife's candidate medical device, currently in development, designed to bring an antibiotic-free, acid-free, dual-action approach to recurrent BV and thrush.
How is BiotaLife different from antibiotics or antifungals?
Rather than indiscriminately killing bacteria, BiotaLife's approach is designed to selectively support protective lactobacilli, working with the body's own microbiome.
When does BloomCalma launch?
BloomCalma launches in November 2026, formulated for comfort during pregnancy and postpartum.